ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney ...

AI is enabling clinical trial sponsors to consider endpoint options beyond traditional design limitations, improving trial design decisions. Regulatory expectations on sponsor oversight of outsourced CRO work emphasize robust, connected documentation to pass inspections. Additionally, the FDA approved a new combination drug for advanced kidney cancer with improved progression metrics.

This Wire brief sits within Fusion42's coverage of Drug Discovery.